Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP-120 (Ifenprodil) for IPF with cough as its key indication. As a result, the Company further announces…

Source